Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine Open-Label Extension for TBI
NCT00219245Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2002
- Primary completion
- Jan 2005
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 4 trial of rivastigmine in traumatic brain injury (TBI), sponsored by Novartis. Started Nov 2002; status: completed.
02
Drugs
rivastigmine
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT00219245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219245.